ASH 2020: Building Toward the Future of Myeloma Care
It is that time of year again: the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition is rapidly approaching, in a virtual format of course, and abstracts have been released for review. We have seen a pattern at ASH in 2018 and 2019, which now continues in 2020. Many ASH abstracts detail immune and genetic findings (myeloma biology); novel immune therapies dominate the schedule; and we have important updates on key trials whose earlier results have already been reported. This is how you build the future of myeloma care—understand the disease better, introduce or update information on cutting-edge new therapies, and consolidate the current standards of care. Read more here.